Aquestive Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Aquestive Therapeutics, Inc. (AQST) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.88M, a 53.60% increase year-over-year.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.32M, a 46.06% increase year-over-year.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.78M, a 76.09% increase year-over-year.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.88M, a 23.11% increase year-over-year.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $7.54M, a 6.87% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.06M.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was -$11.00K, a 100.25% decline from fiscal 2022.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.37M, a 35.67% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.88M 10-Q · filed 2026-08-11 | $5.20M derived: sum of 2 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $2.32M 10-Q · filed 2026-08-11 | |||||
| 2025-12-31 | $7.54M 10-K · filed 2026-03-04 | |||||
| 2025-09-30 | $2.78M 10-Q · filed 2025-11-05 | $4.65M derived: sum of 2 quarters · filed 2026-08-11 | $6.24M derived: sum of 3 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $1.88M 10-Q · filed 2026-08-11 | $3.46M derived: sum of 2 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $1.59M 10-Q · filed 2026-08-11 | |||||
| 2024-12-31 | $7.06M 10-K · filed 2026-03-04 | -$1.35M 10-K · filed 2025-03-05 | ||||
| 2024-09-30 | $1.58M 10-Q · filed 2025-11-05 | $3.10M derived: sum of 2 quarters · filed 2025-11-05 | $4.68M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $1.52M 10-Q · filed 2025-11-05 | $3.10M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $1.58M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | -$11.00K 10-K · filed 2025-03-05 | $2.66M 10-K · filed 2024-03-05 | ||||
| 2023-09-30 | $774.00K 10-Q · filed 2024-11-04 | $1.41M derived: sum of 2 quarters · filed 2024-11-04 | $1.75M derived: sum of 3 quarters · filed 2024-11-04 | |||
| 2023-06-30 | $631.00K 10-Q · filed 2024-11-04 | $975.00K derived: sum of 2 quarters · filed 2024-11-04 | ||||
| 2023-03-31 | $344.00K 10-Q · filed 2024-11-04 | |||||
| 2022-12-31 | $4.37M 10-K · filed 2024-03-05 | |||||
| 2022-09-30 | $535.00K 10-Q · filed 2023-11-06 | $2.75M derived: sum of 2 quarters · filed 2023-11-06 | $3.67M derived: sum of 3 quarters · filed 2023-11-06 | |||
| 2022-06-30 | $2.22M 10-Q · filed 2023-11-06 | $3.13M derived: sum of 2 quarters · filed 2023-11-06 | ||||
| 2022-03-31 | $913.00K 10-Q · filed 2023-11-06 | |||||
| 2021-12-31 | $6.79M 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $1.90M 10-Q · filed 2022-11-01 | $3.61M derived: sum of 2 quarters · filed 2022-11-01 | $5.12M derived: sum of 3 quarters · filed 2022-11-01 | |||
| 2021-06-30 | $1.71M 10-Q · filed 2022-11-01 | $3.22M derived: sum of 2 quarters · filed 2022-11-01 | ||||
| 2021-03-31 | $1.51M 10-Q · filed 2022-11-01 | |||||
| 2020-12-31 | $6.56M 10-K · filed 2022-03-08 | |||||
| 2020-09-30 | $1.42M 10-Q · filed 2021-11-02 | $3.17M derived: sum of 2 quarters · filed 2021-11-02 | $5.03M derived: sum of 3 quarters · filed 2021-11-02 | |||
| 2020-06-30 | $1.75M 10-Q · filed 2021-11-02 | $1.70M 10-Q · filed 2020-08-04 | $3.61M derived: sum of 2 quarters · filed 2021-11-02 | |||
| 2020-03-31 | $1.86M 10-Q · filed 2021-11-02 | $1.82M 10-Q · filed 2020-05-05 | ||||
| 2019-12-31 | $7.04M 10-K · filed 2021-03-09 | $6.72M 10-K · filed 2020-03-11 | ||||
| 2019-09-30 | $1.81M 10-Q · filed 2020-11-04 | $3.55M derived: sum of 2 quarters · filed 2020-11-04 | $4.97M derived: sum of 3 quarters · filed 2020-11-04 | |||
| 2019-06-30 | $1.74M 10-Q · filed 2020-11-04 | $3.16M derived: sum of 2 quarters · filed 2020-11-04 | ||||
| 2019-03-31 | $1.42M 10-Q · filed 2020-11-04 | |||||
| 2018-12-31 | $2.28M 10-K · filed 2020-03-11 | |||||
| 2018-09-30 | $995.00K 10-Q · filed 2019-11-05 | $1.00M derived: sum of 2 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $7.00K 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |